[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bach Mai Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":209},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,81,112,145,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100639092","low-dose-rocuronium-maintenance-during-spine-surgery-with-intraoperative-neurophysiological-monitoring-100639092",false,"NCT07627750","Low-Dose Rocuronium Maintenance During Spine Surgery With Intraoperative Neurophysiological Monitoring","A Randomized Controlled Trial Comparing Low-Dose Rocuronium Maintenance Versus Discontinuation After Induction on Motor Evoked Potential Quality During Spine Surgery With Intraoperative Neurophysiological Monitoring","ROC-IONM","Inclusion Criteria:\n\n\\- 1. Patients aged 18 years or older. 2. Patients scheduled for spine surgery under general anesthesia. 3. Patients undergoing spine surgery with intraoperative neurophysiological monitoring, including motor evoked potentials and\u002For somatosensory evoked potentials.\n\n4\\. Patients who agree to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* 1\\. Pre-existing central or peripheral neurological disease that may affect intraoperative neurophysiological monitoring, such as quadriplegia, persistent sensory disorder, sequelae of stroke, or polyneuropathy.\n\n  2\\. History of epilepsy or electroencephalographic disorder. 3. Use of neuropsychiatric drugs, strong sedatives, or drugs affecting neuromuscular or neurological conduction within 48 hours before surgery.\n\n  4\\. Decompensated cardiovascular disease or severe respiratory disease that may affect emergence or anesthetic drug metabolism.\n\n  5\\. Contraindication to intraoperative neurophysiological monitoring. 6. Contraindication to rocuronium. 7. Refusal to participate or withdrawal of consent at any time..","ALL","18 Years",{"count":20,"type":21},62,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized controlled trial will compare two strategies for rocuronium use during general anesthesia for spine surgery with intraoperative neurophysiological monitoring. Participants undergoing spine surgery under general anesthesia with motor evoked potential and\u002For somatosensory evoked potential monitoring will be randomized to either low-dose rocuronium maintenance targeting a train-of-four ratio of 0.60 to less than 0.90, or no rocuronium maintenance after induction.\n\nThe main objective is to compare the effects of these two strategies on the quality of intraoperative neurophysiological monitoring, especially motor evoked potential signals. Secondary objectives include comparing surgical field conditions, unwanted patient movement, emergence and extubation times, early respiratory events, and new postoperative neurological deficits.\n\nThe study will be conducted at the Center for Anesthesia and Surgical Intensive Care, Bach Mai Hospital, Hanoi, Vietnam. The planned sample size is 62 participants, with 31 participants in each group.",[27,28,29],"Spine Surgery","Intraoperative Neurophysiological Monitoring","Neuromuscular Blockade",[31,32,33,34,27,28,35],"Rocuronium","Motor Evoked Potentials","Somatosensory Evoked Potentials","Train-of-Four Ratio","Total Intravenous Anesthesia","NOT_YET_RECRUITING","2026-05-30",{"date":39,"type":40},"2026-06-04","ACTUAL",{"date":42,"type":21},"2026-06",{"date":44,"type":21},"2028-12",{"name":46,"class":47},"Bach Mai Hospital","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100639926","predictors-of-clinically-relevant-hypotension-and-hypoxemia-during-propofol-based-diagnostic-gastrointestinal-endoscopy-100639926","NCT07613073","Predictors of Clinically Relevant Hypotension and Hypoxemia During Propofol-Based Diagnostic Gastrointestinal Endoscopy","Independent Predictors of Clinically Relevant Hypotension and Hypoxemia During During Propofol-Based Diagnostic Gastrointestinal Endoscopy: A Prospective Cohort Study","PRO-GI SAFE","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled for diagnostic esophagogastroduodenoscopy, diagnostic colonoscopy, or combined diagnostic upper and lower gastrointestinal endoscopy\n* Planned use of propofol as the primary sedative\u002Fanesthetic agent for diagnostic gastrointestinal endoscopy\n* American Society of Anesthesiologists physical status I to III\n* Able to provide informed consent or has legally authorized representative consent according to local regulations\n\nExclusion Criteria:\n\n* Therapeutic or interventional gastrointestinal endoscopy, including ERCP, EUS-guided intervention, EMR, ESD, endoscopic hemostasis, or polypectomy\n* Planned sedation\u002Fanesthesia without propofol as the primary sedative\u002Fanesthetic agent\n* Known allergy or contraindication to propofol\n* Pregnancy or suspected pregnancy\n* Emergency condition requiring immediate advanced airway control before the procedure\n* Inability to obtain essential baseline or outcome data required for the study",{"count":57,"type":21},1000,"OBSERVATIONAL","This prospective observational cohort study will evaluate the incidence and independent predictors of clinically relevant hypotension and hypoxemia during propofol-based diagnostic gastrointestinal endoscopy in adult patients at a tertiary referral hospital in Vietnam. Participants undergoing diagnostic upper gastrointestinal endoscopy, colonoscopy, or combined diagnostic procedures with propofol administration will be followed from pre-procedure assessment through the early recovery period. The study will assess demographic, clinical, airway, procedural, and sedation-related variables associated with clinically relevant cardiopulmonary adverse events.",[61,62],"Hypotension","Hypoxemia",[64,65,66,67,68,69,70,71],"Propofol sedation","Gastrointestinal endoscopy","Colonoscopy","Upper gastrointestinal endoscopy","Oxygen desaturation","Hemodynamic instability","Prospective cohort","Procedural sedation","2026-05-21",{"date":74,"type":40},"2026-05-29",{"date":76,"type":21},"2026-05-15",{"date":78,"type":21},"2026-10-30",{"name":46,"class":47},1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":92,"studyType":58,"phases":4,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":80},"100634426","comparing-traditional-risk-scores-and-an-ai-based-multimodal-model-for-predicting-cardiovascular-events-after-gastrointestinal-surgery-100634426","NCT07539532","Comparing Traditional Risk Scores and an AI-Based Multimodal Model for Predicting Cardiovascular Events After Gastrointestinal Surgery","Value of Some Risk Scores in Predicting Cardiovascular Events After Gastrointestinal Surgery","GI-MACE-AI","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Undergoing gastrointestinal surgery at Bach Mai Hospital between January 2025 and December 2026.\n* Available preoperative, intraoperative, and postoperative data sufficient for analysis.\n\nExclusion Criteria:\n\n* Death within 24 hours after surgery due to a clearly non-cardiovascular cause.\n* Incomplete data required for analysis.","16 Years",{"count":91,"type":21},5000,"30 Days","The goal of this observational study is to develop and evaluate an artificial intelligence (AI)-based multimodal model for predicting major cardiovascular events within 30 days after gastrointestinal surgery in adults at Bach Mai Hospital. The study will also compare the predictive performance of this AI-based model with commonly used traditional risk scores.\n\nThe main questions it aims to answer are:\n\nCan an AI-based multimodal model predict major cardiovascular events within 30 days after gastrointestinal surgery? Does the AI-based model show better predictive performance than the Revised Cardiac Risk Index (RCRI), the American College of Surgeons National Surgical Quality Improvement Program Myocardial Infarction or Cardiac Arrest calculator (ACS NSQIP MICA), and the ACS NSQIP Surgical Risk Calculator (ACS NSQIP SRC)? Researchers will compare the AI-based multimodal model with traditional risk scores using measures of predictive performance, including discrimination, calibration, net reclassification improvement, and integrated discrimination improvement.\n\nParticipants will be adults undergoing gastrointestinal surgery. Researchers will review medical record data from patients treated in 2025 and will also collect the same types of clinical data prospectively in 2026. The clinical outcome being predicted is the occurrence of major cardiovascular events within 30 days after surgery. The study will not change routine clinical care.",[95,96,97],"Postoperative Complications","Cardiovascular Diseases","Digestive System Surgical Procedures",[99,100,101,102],"Major adverse cardiovascular events","Gastrointestinal surgery","Artificial intelligence","Multimodal model","RECRUITING","2026-04-16",{"date":106,"type":40},"2026-04-20",{"date":108,"type":40},"2026-01-01",{"date":110,"type":21},"2026-07-31",{"name":46,"class":47},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":80},"100628481","phase-4-dexmedetomidine-for-improving-emergence-quality-in-thyroid-surgery-100628481","NCT07462195","Dexmedetomidine for Improving Emergence Quality in Thyroid Surgery","Effect of Perioperative Dexmedetomidine Infusion on Anesthetic Requirements and Quality of Emergence in Patients Undergoing Thyroid Surgery: A Randomized Controlled Trial","DEX-THYROID","Inclusion Criteria:\n\n* Age 18-65 years.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Scheduled for elective thyroid surgery (thyroidectomy) under general anesthesia with endotracheal intubation.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindication to dexmedetomidine or study-related medications.\n* Clinically significant cardiac conduction abnormality or arrhythmia (e.g., second- or third-degree atrioventricular block without a pacemaker), severe bradyarrhythmia, or unstable cardiovascular disease.\n* Severe hepatic dysfunction or severe renal failure.\n* Pregnancy or breastfeeding.\n* Planned postoperative ICU admission or postoperative deterioration requiring ICU admission.\n* Major intraoperative complications (e.g., major bleeding requiring urgent hemostatic intervention, tracheal or esophageal injury, or recurrent laryngeal nerve injury identified intraoperatively).\n* Any condition that, in the investigator's judgment, would interfere with outcome assessment or increase risk (e.g., inability to reliably report pain scores or complete QoR-15).","65 Years",{"count":122,"type":21},100,[124],"PHASE4","Thyroid surgery requires smooth emergence from anesthesia to minimize coughing, hemodynamic fluctuations, and agitation during extubation, which may contribute to postoperative complications such as bleeding or cervical hematoma. Dexmedetomidine, a selective α2-adrenergic receptor agonist, has sedative, analgesic-sparing, and sympatholytic properties that may improve anesthetic stability and recovery quality.\n\nThis randomized controlled trial aims to evaluate the effectiveness of a continuous perioperative dexmedetomidine regimen initiated at induction of anesthesia and maintained during thyroid surgery.\n\nThe study will compare dexmedetomidine combined with standard balanced anesthesia versus standard anesthesia alone in terms of anesthetic requirements and emergence quality.\n\nThe primary hypothesis is that perioperative dexmedetomidine administration reduces anesthetic and opioid requirements and improves emergence quality by decreasing coughing during extubation and hemodynamic responses.",[127],"Thyroid Diseases",[129,130,131,132,133,134,135,136],"Dexmedetomidine","Thyroidectomy","General Anesthesia","Extubation Cough","Emergence Agitation","Postoperative Nausea and Vomiting","Anesthetic Requirement","Quality of Recovery","2026-04-12",{"date":139,"type":40},"2026-04-15",{"date":141,"type":40},"2026-04-13",{"date":143,"type":21},"2026-11-30",{"name":46,"class":47},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":80},"100633677","phase-4-low-dose-norepinephrine-infusion-for-prevention-of-post-induction-hypotension-in-emergency-surgery-for-peritonitis-100633677","NCT07529795","Low-dose Norepinephrine Infusion for Prevention of Post-induction Hypotension in Emergency Surgery for Peritonitis","Protocolized Low-dose Norepinephrine Infusion for Prevention of Post-induction Hypotension in Adults Undergoing Emergency Surgery for Secondary Peritonitis: A Randomized Double-blind Placebo-controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Secondary peritonitis requiring emergency surgery under general anesthesia with endotracheal intubation.\n* Planned induction with fentanyl, propofol, and rocuronium according to the study protocol.\n* Hemodynamically stabilized after initial resuscitation, with MAP at least 65 mmHg and no ongoing vasopressor infusion before induction.\n* ASA physical status I to III.\n* Written informed consent from the participant or a legally authorized representative.\n\nExclusion Criteria:\n\n* Allergy or contraindication to norepinephrine, propofol, fentanyl, or rocuronium.\n* Severe cardiovascular disease likely to confound hemodynamic assessment, including decompensated heart failure, acute coronary syndrome, severe arrhythmia, severe valvular disease, or major cardiomyopathy.\n* Ongoing vasopressor therapy before induction.\n* Shock before surgery, including hypovolemic, septic, or cardiogenic shock.\n* Severe hypertension before induction (systolic blood pressure \\>180 mmHg or mean arterial pressure \\>110 mmHg).\n* Severe peripheral vascular disease or clinically significant limb ischemia.\n* Current monoamine oxidase inhibitor use.\n* Pregnancy or breastfeeding.\n* Contraindication to arterial catheter placement.\n* Refusal of consent.",{"count":153,"type":21},60,[124],"This study tests whether giving a low-dose norepinephrine infusion just before induction of anesthesia can reduce low blood pressure during emergency surgery for peritonitis. Adults with secondary peritonitis who are scheduled for emergency surgery and have stable blood pressure after initial resuscitation will be randomly assigned to receive either norepinephrine or placebo (normal saline) during induction of anesthesia. The main outcome is the cumulative time spent with mean arterial pressure (MAP) below 65 mmHg from the start of propofol administration to 10 minutes after endotracheal intubation. The study will also evaluate rescue vasopressor use, heart rate changes, drug-related adverse events, and selected early postoperative outcomes.",[157,158],"Secondary Peritonitis","Post-induction Hypotension",[160,161,162,163,164,165],"Emergency surgery","General anesthesia","Norepinephrine","Noradrenaline","Induction hypotension","Mean arterial pressure","2026-04-07",{"date":168,"type":40},"2026-04-14",{"date":170,"type":21},"2026-04-01",{"date":172,"type":21},"2026-10",{"name":46,"class":47},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":194,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":80},"100597765","the-role-of-swan-ganz-catheter-in-hemodynamic-resuscitation-for-patients-with-cardiogenic-shock-100597765","NCT07062744","The Role of Swan-Ganz Catheter in Hemodynamic Resuscitation for Patients With Cardiogenic Shock","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Provided written informed consent to participate in the study.\n* Diagnosed with cardiogenic shock due to acute myocardial infarction according to IABP-SHOCK II (2012) criteria:\n\n  * Systolic blood pressure (SBP) \\\u003C 90 mmHg for at least 30 minutes, or requiring vasopressor agents to maintain SBP \\> 90 mmHg.\n  * Evidence of end-organ hypoperfusion, indicated by at least one of the following: Altered mental status, Urine output \\\u003C 30 mL\u002Fhour, Cold extremities with mottled skin, Serum lactate level \\> 2 mmol\u002FL.\n\nExclusion Criteria:\n\n* Presence of cervical cellulitis.\n* Inability to identify neck anatomy or history of cervical radiotherapy.\n* Coagulopathy (INR \\> 1.5 and\u002For platelet count \\\u003C 50 G\u002FL).\n* End-stage chronic diseases, including: Advanced malignancy, advanced-stage HIV, bedridden patients for more than 3 months, decompensated liver cirrhosis (Child-Pugh class C).\n* Patients with cardiac arrest or mechanical complications such as myocardial rupture prior to Swan-Ganz catheterization.\n* Congenital heart defects or intracardiac shunts. Refusal of participation by the patient or their legal representative.",{"count":181,"type":21},108,[24],"This clinical trial examines whether the use of the Swan-Ganz catheter, a specialized pulmonary artery catheter, can improve hemodynamic management and treatment outcomes in patients experiencing cardiogenic shock due to acute myocardial infarction (AMI).\n\nCardiogenic shock is a critical condition marked by the heart's inability to supply adequate blood to the organs, often resulting from a severe heart attack. Despite advancements in care, the condition remains associated with high mortality. Effective monitoring of cardiovascular status is crucial in guiding timely and tailored treatment decisions.\n\nParticipants in this study will undergo advanced hemodynamic monitoring using the Swan-Ganz catheter, which provides continuous data on cardiac output and other key parameters. This information enables physicians to better assess circulatory function and adjust therapies accordingly.\n\nThe research will evaluate clinical characteristics, response to treatment, and 30-day outcomes in patients managed with this technique. The study also aims to identify factors associated with successful hemodynamic stabilization and potential complications related to catheter use.\n\nA total of 108 adult patients meeting specific eligibility criteria will be enrolled at Bach Mai Hospital over 3 years. Participation is voluntary, and all patients will continue to receive standard-of-care treatment. All personal and medical data will be handled with strict confidentiality.",[185,186,187,188,189,190,191,192,193],"Cardiogenic Shock","Pulmonary Artery Catheter Waveform Interpretation","Hemodynamic Management","Hemodynamic Optimization","Hemodynamic Monitoring","Acute Myocardial Infarction (AMI)","Critical Care, Intensive Care","Emergency","Cardio Vascular Disease",[195,196,197,198,199,200],"Swan-Ganz","Pulmonary Artery Catheter","Cardiogenic shock","Hemodynamic management","Invasive hemodynamic","Right Heart Catheter","2025-07-10",{"date":203,"type":40},"2025-07-14",{"date":205,"type":40},"2025-05-27",{"date":207,"type":21},"2027-12-30",{"name":46,"class":47},""]